Weekly Recap

NeurologyLive Weekly Recap

Each week on Saturday morning, the NeurologyLive^® team puts together a weekly recap that offers a quick look into some of the top headlines in neurology news that you may have missed.

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

Siponimod Approved for SPMS, AVP-786 Phase 3 Results for Treatment of Agitation in Alzheimer-Related Dementia, and Mobile Technology for Care of Parkinson Disease

NeurologyLive® Staff

March 30th 2019

Neurology News Network for the week of March 30, 2019.

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

Quality of Life is Predictive of DBS Outcomes in Early Parkinson, Lack of Approved Therapies for MS Symptoms, and Ubrogepant for Acute Treatment of Migraine in Adults

NeurologyLive® Staff

March 23rd 2019

Neurology News Network for the week of March 22, 2019.

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

NDA Accepted for SRP-4053 for DMD, MPRI 2.0 Differentiates Parkinson and Progressive Supranuclear Palsy, and Young Donor Plasma Infusion Warning

NeurologyLive® Staff

February 23rd 2019

Neurology News Network for the week of February 23, 2019.

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

Patients with Parkinson at Greater Risk for Dementia After DBS Implant, a Novel ALS Diagnostic Index, Preliminary IGNITE-DMD Trial Findings

NeurologyLive® Staff

February 16th 2019

Neurology News Network for the week of February 14, 2019.

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

SPRINT-MIND Trial Results, Alemtuzumab and Rituximab Safe for MS, CAP-1002 for Duchenne Muscular Dystrophy

NeurologyLive® Staff

February 2nd 2019

Neurology News Network for the week of February 2, 2019.

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

Ocrelizumab Compared to Other DMTs, Effects of Lemborexant on Next-Day Driving, BHV-3241 Gets FDA OK for Clinical Trial

NeurologyLive® Staff

January 26th 2019

Neurology News Network for the week of January 26, 2019.

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

AHS Statement on CGRP Inhibitors, NDA Submitted for Lemborexant, Dabigatran Assessed in Alzheimer

NeurologyLive® Staff

January 19th 2019

Neurology News Network for the week of January 19, 2019.

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

Fumarate Bioequivalent for MS, Embrace Smartband Approval, Alzheimer Biomarkers Identified, Long-Term Perampanel Data

NeurologyLive® Staff

January 12th 2019

Neurology News Network for the week of January 12, 2019.

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

Solriamfetol PDUFA Date Pushed, Recognizing Parkinson Disease, Chronic Migraine Peer Exchange Program

NeurologyLive® Staff

January 5th 2019

Neurology News Network for the week of January 5, 2019.

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

Oxtellar XR Approved as Monotherapy, Pregnancy Safety Data for Betaseron, and Biologic Brain Changes in Migraine

NeurologyLive® Staff

December 22nd 2018

Neurology News Network for the week of December 22, 2018.

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

Zilucoplan for Mysathenia Gravis, AXS-05 for Agitation in Alzheimer, and Chronic Migraine Management

NeurologyLive® Staff

December 15th 2018

Neurology News Network for the week of December 15, 2018.

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

Fingolimod Issued a Safety Warning, an NDA for BHV-0223 for ALS, and Lifestyle Modifications for Patients with Migraine

NeurologyLive® Staff

December 8th 2018

Neurology News Network for the week of December 1, 2018.

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

Galcanezumab for Cluster Headache, a Link Between Carotid Webs and Stroke, Managing Migraine Patient Relationships

NeurologyLive® Staff

November 24th 2018

Neurology News Network for the week of November 24, 2018.

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use

NeurologyLive® Staff

November 17th 2018

Neurology News Network for the week of November 17, 2018.

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

Confounding Outcomes in Alzheimer, AFib and Dementia Risk, Cognitive Issues in Epilepsy, and MRI Imaging

NeurologyLive® Staff

November 10th 2018

Neurology News Network for the week of November 10, 2018.

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

Sodium Oxybate Approved, ANAVEX 2-73 Shows Positive Results, Ubrogepant for Acute Migraine Care, and Stroke Risk with Migraine

NeurologyLive® Staff

November 3rd 2018

Neurology News Network for the week of November 3, 2018.

Novel Deep Brain Stimulation System, ITI-214 Safe for Parkinson Disease, Elizabeth Ross on the Field's Progress

Novel Deep Brain Stimulation System, ITI-214 Safe for Parkinson Disease, Elizabeth Ross on the Field's Progress

NeurologyLive® Staff

October 27th 2018

Neurology News Network for the week of Oct. 27, 2018.

New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS

New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS

NeurologyLive® Staff

October 20th 2018

Neurology News Network for the week of October 20, 2018.

Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy

Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy

NeurologyLive® Staff

October 13th 2018

Neurology News Network for the week of Oct. 12, 2018.

Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well

Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well

NeurologyLive® Staff

October 6th 2018

Neurology News Network for the week of October 6, 2018.

Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer

Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer

NeurologyLive® Staff

September 29th 2018

Neurology News Network for the week of September 28, 2018.

FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS

FDA Approves Fremanezumab, Behavioral Activation Therapy for MCI, Choosing DMTs for MS

NeurologyLive® Staff

September 22nd 2018

Neurology News Network for the week of September 22, 2018.

XEN496 for KCNQ2 Epileptic Encephalopathy, the State of Acute Stroke Care, and Ocrelizumab's Success

XEN496 for KCNQ2 Epileptic Encephalopathy, the State of Acute Stroke Care, and Ocrelizumab's Success

NeurologyLive® Staff

September 15th 2018

Neurology News Network for the week of September 15, 2018.

...

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.